Cogentis Therapeutics
PrivateLast Round
Grant
Apr 30, 2020
Total Funding Raised
$188,193
Company Overview
Cogentis Therapeutics operates in Healthcare & Life Sciences and is based in Columbia, Maryland. Its latest recorded funding round was a Grant round in April 2020.
Cogentis Therapeutics is a biotechnology company that develops disease-modifying therapeutics for neurodegenerative diseases such as Alzheimer's, Parkinson's, and frontotemporal dementia.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Cogentis Therapeutics Comparables
Compare Cogentis Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| 4M Therapeutics | 88% | |
| Teitur Trophics | 80% | |
| Perha Pharmaceuticals | 71% |
For institutional investors. Book with your work email.
Cogentis Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Apr 30, 2020 | ||||
| Accelerator | May 21, 2015 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Cogentis Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The Association for Frontotemporal Degeneration | Grant |
| MassChallenge Israel | Accelerator |
| Alzheimer's Drug Discovery Foundation | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 2, 2026
Monthly visitors increased 349% MoM.
- May 21, 2015
Received funding from MassChallenge Israel and The Center for Advancing Innovation.
For institutional investors. Book with your work email.
Cogentis Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Cogentis Therapeutics's valuation, stock price, and market status.
Is Cogentis Therapeutics a public or private company?
Cogentis Therapeutics is a private company.
What is the current stock price of Cogentis Therapeutics?
Cogentis Therapeutics is a private company, so its shares have no public market price. Caplight tracks Cogentis Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Cogentis Therapeutics worth (valuation)?
Valuation information for Cogentis Therapeutics is not publicly available.
Can I buy Cogentis Therapeutics stock?
Cogentis Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Cogentis Therapeutics's last funding round?
Cogentis Therapeutics's most recent funding round was Grant on April 30, 2020.
Who are the main investors in Cogentis Therapeutics?
Key investors in Cogentis Therapeutics include Alzheimer's Drug Discovery Foundation.
Will Cogentis Therapeutics IPO soon?
No public IPO plans have been announced for Cogentis Therapeutics.
How can I track Cogentis Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Cogentis Therapeutics's shares on secondary markets.